Evaluation of synthetic, M type-specific peptides as antigens in a multivalent group A streptococcal vaccine

Vaccine

Volumn 21, Issue 21-22, 2003, Pages 2698-2703

  Bruner, M ^a   James, A ^a   Beall, B ^a   Carlone, G M ^a   Ades, E ^a   Johnson, S ^a   Guarner, J ^a   Sampson, J ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

Author keywords

Group A streptococci; Group A streptococci peptide vaccine; M protein; Streptococcus pyogenes

Indexed keywords

PROTEIN; PROTEIN M; STREPTOCOCCUS VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG SCREENING; FEMALE; IMMUNE RESPONSE; IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; IN VIVO STUDY; MOUSE; NASOPHARYNX; NONHUMAN; PRIORITY JOURNAL; PROVOCATION TEST; SEROTYPE; STREPTOCOCCUS GROUP A; STREPTOCOCCUS INFECTION;

EID: 0037837018     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(03)00165-8     Document Type: Article

References (21)

1. Brandt E.R., Good M.F. Vaccine strategies to prevent rheumatic fever. Immunol. Res. 19:1999;89-103.
2. O'Brien K.L., Beall B., Barrett N.L., Cieslak M.D., Reingold A., Farley M.M.et al. Epidemiology of invasive group A streptococcus disease in the United States, 1995-1999. Clin. Infect. Dis. 35:2002;268-276.
3. Davies H.D., McGeer A., Schwartz B.et al. Invasive group A streptococcal infections in Ontario, Canada. Ontario Group A Streptococcal Study Group. N. Engl. J. Med. 335:1996;547-554.
4. Veasey L.G., Wiedneier S.W., Osmond G.S.et al. Resurgence of acute rheumatic fever in the intermountain region of the United States. N. Engl. J. Med. 316:1987;421-427.
5. Bessen D., Fischetti V.A. Synthetic peptide vaccine against mucosal colonization by group A streptococci. J. Immunol. 145:1990;1251-1256.
6. Salvadori L.G., Blake M.S., McCarty M., Tai J.Y., Zabriskie J.B. Group A streptococcus-liposome ELISA antibody titers to group A polysaccharide and opsonophagocytic capabilities of the antibodies. J. Infect. Dis. 171:1995;593-600.
7. Ji Y., Carlson B., Kondagunta A., Cleary P.P. Intranasal immunization with C5a peptidase prevents nasopharyngeal colonization of mice by group A streptococcus. Infect. Immun. 65:1997;2080-2087.
8. Kapur V., Maffei J.T., Greer R.S., Li L.L., Adams G.J., Musser J.M. Vaccination with streptococcal cysteine protease protects mice against challenge with heterologous group A streptococci. Microb. Pathog. 16:1994;443-450.
9. Dale J.B., Baird R.W., Courtney H.S., Hasty D.L., Bronze M.S. Passive protection of mice against group A streptococcal pharyngeal infection by lipoteichoic acid. J. Infect. Dis. 169:1994;319-323.
10. Dale J.B., Washburn R.G., Marques M.B., Wessels M.R. Hyuaronated capsule and surface M protein in resistance to opsonization of group A streptococci. Infect. Immun. 64:1996;1495-1501.
11. Medaglini D., Pozzi G., King T.P., Fischetti V.A. Mucosal and systemic immune responses to a recombinant protein expressed on the surface of oral commensal bacterium Streptococcus gordonii after oral colonization. Proc. Natl. Acad. Sci. U.S.A. 92(15):1995;6868-6872.
12. Dale J.B., Simmons M., Chiang E.C., Chiang E.Y. Recombinant, octavalent group A streptococcal M protein vaccine. Vaccine. 14:1996;944-948.
13. Brandt E.R., Sriprakash K.S., Hobb R.I., Hayman W.A., Zeng W., Batzloff M.R. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population. Nat. Med. 6:2000;455-459.
14. Hu M.C., Walls M.A., Stroop S.D., Reddis M.A., Beall B., Dale J.B. Pre-clinical evaluation of a 26-valent group A streptococcal vaccine. Infect. Immun. 70:2002;2171-2177.
15. Fischetti V.A. Streptococcal M protein: molecular design and biological behavior. Clin. Microbiol. 2:1989;285-314.
16. Lancefield R.C. Current knowledge of the type-specific M antigens of group A streptococci. J. Immun. 89:1962;307-313.
17. Lancefield R.C. Persistence of type-specific antibodies in man following infection with group A streptococci. J. Exp. Med. 110:1959;271-283.
18. Beall B., Facklam R., Thompson T. Sequencing emm-specific PCR products for routine and accurate typing of group A streptococci. J. Clin. Microbiol. 34:1996;953-958.
19. Beall B., Facklam R., Hoenes T., Schwartz B. A survey of emm gene sequences from systemic Streptococcus pyogenes infection isolates collected in San Francisco, CA; Atlanta, GA; and Connecticut state in 1994 and 1995. J. Clin. Microbiol. 35:1997;1231-1235.
20. Quinn A., Ward K., Fischetti V.A., Hemric M., Cunningham M.W. Immunological relationship between the class I epitope of streptococcal M protein and myosin. Infect. Immun. 66(9):1998;4418-4424.
21. Johnson S.E., Dykes J.K., Ju D.L., Sampson J.S., Carlone G.M., Ades E.W. Inhibition of pneumococcal carriage in mice by subcutaneous immunization with peptides from the common surface protein pneumococcal surface adhesin A. J. Infect. Dis. 185:2002;489-496.